| Detailed information |
|---|
| CancerLivER ID | 2462 |
| Biomarker | SMYD3, FABP1, Ceruloplasmin, A2M, IGFBP, PPAP2B, SHMT, PHLDA1, APOA1, SOCS2, ETS2, MT2A, CYP39A1, HAMP, CYP2C9, SLC22A1, PLG, GAMT, FGG, KRT8, IFITM1, C1R, FGB, FGA, GC (vitamin D binding protein), SERPINA3, WAC, |
| Biomarker Name/Symbol (given in Publication) | SMYD3 or SET and MYND domain containing 3, FABP1 or Fatty acid binding protein 1 liver, CP or Ceruloplasmin (ferroxidase), A2M or ·-2-macroglobulin, IGFBP3 or Insulin-like growth factor binding protein 3, PPAP2B or Phosphatidic acid phosphatase type 2B, SHMT1 or Serine hydroxymethyltransferase 1, PHLDA1 or Pleckstrin homology-like domain family A member 1, APOA1 or Apolipoprotein A-I, SOCS2 or Suppressor of cytokine signaling 2, ETS2 or V-ets erythroblastosis virus E26 oncogene homolog 2, MT2A or Metallothionein 2A, CYP39A1 or Cytochrome P450 family 39 subfamily A polypeptide 1, HAMP or Hepcidin antimicrobial peptide, CYP2C9 or Cytochrome P450 family 2 subfamily C polypeptide 9, SLC22A1 or Solute carrier family 22 member 1, PLG or Plasminogen, GAMT or Guanidinoacetate N-methyltransferase, FGG or Fibrinogen à polypeptide, - or EST, KRT8 or Keratin 8, IFITM1 or Interferon induced transmembrane protein 1, C1R or Complement component 1 r subcomponent, FGB or Fibrinogen B ß polypeptide, FGA or Fibrinogen A · polypeptide, GC or Group-specific component (vitamin D binding protein), SERPINA3 or Serine proteinase inhibitor clade A member 3, WAC or WW domain-containing adapter with a coiled-coil region |
| Biomolecule | RNAs |
| Subject | Human |
| Degree of Validity | Potential diagnostic marker for HCC; but not validated on independent dataset |
| Experimental Condition | HCC v/s non-tumor |
| Cancer type | Hepatocellular carcinoma |
| Regulation | Upregulated in among all types HCC v/s non-tumor |
| Level of significance | p < 0.01 |
| Source | Tissue |
| PMID | 16391793 |
| Type of Biomarker | Diagnostic |
| Pathway | Regulation of cellular process, Regulation of cell proliferation, |
| Cohort | 204 (119 tumor and 85 non-tumor) HCC patients: HCV group (n=80), HBV group (n=19) and non-B, non-C group (n=20) |
| Sensitivity | NA |
| Specificity | NA |
| Accuracy | NA |
| AUC | NA |
| Disease | HCV and HBV - associated HCC and Non-HCV/HBV associated HCC |
| Year of Publication | 2006 |
| Clinical trial | NO |
| Clinical trial (NCT Number) | NA |